Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ...
Going against prevailing market trends can be tricky, but it can also be a rewarding strategy. Uncovering gems in the stock market that most other investors are ignoring -- or actively avoiding -- can be highly profitable in the long term. Of course, scooping up shares of beaten-down stocks...
Switzerland's Roche (OTCQX:RHHBY) (OTCQX:RHHBF) and bluebird bio (BLUE) are resolving a trademark infringement litigation related to the Cambridge, Mass.-based gene therapy company's sickle cell disease (SCD) awareness campaign, "Be the Spark," Fierce Pharma reported. Roche's gene t...
Bluebird bio (NASDAQ:BLUE) stock rose ~6% on May 17 amid Morgan Stanley lowering its price target on the gene therapy developer's shares to $3 from $5. Morgan Stanley analyst maintained an Underweight rating on the shares. Following the company's Q1 earnings about a week ago Barclay...
bluebird bio (BLUE +10.1%) Q1 shows a revenue beat of $1.78M to $1.95, up +119.1% Y/Y. Research and development expenses from continuing operations were $77.9 million for the three months ended March 31, 2022, compared to $82.8 million for the three months ended March 31, 2021. Restricted cas...
bluebird bio press release (NASDAQ:BLUE): Q1 GAAP EPS of -$1.66 misses by $0.30. Revenue of $1.95M (+119.1% Y/Y) beats by $1.78M. Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-end 2022 For further details see: bluebird bio GAAP EPS of -$1...
- BLAs for beti-cel for β-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - - Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-en...
Potential to receive FDA approval of beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukoodystrophy in 2022. FDA approvals of beti-cel and eli-cel would give bluebird bio the ability to receive Priority Review Vouchers which it could sell for upwards of over $100 million...
A turnaround plays are highly risky yet you found them in the land of multi-baggers. BioLife shares have tumbled substantially due to various issues like supply-chain that cannot keep pace with the company's growth by acquisition strategy. There are also management changes and the...
The past few years have been harsh on Bluebird Bio (NASDAQ: BLUE) . The rare-diseases-focused, gene-therapy specialist ran into a series of clinical and regulatory headwinds, which played a major role in its catastrophic performance in the stock market since 2019. Bluebird's shares ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ:BLUE). S...
LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
LOS ANGELES, April 24, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...